Today
Xponential Fitness, Inc. Announces Appointment of Danielle Porto Parra as President
a few seconds ago
Allegiant Selects Navan as Employee Travel Platform
a minute ago
Doubleverify Holdings, Inc. DoubleVerify Launches AI-Powered Content-Level Controls on Meta Threads, Strengthening Brand Protection
2 minutes ago
Procter & Gamble Company (the) iHeartMedia and Procter & Gamble (P&G) Launch the Elton John Impact Awards to Honor LGBTQ+ Icons and Trailblazers with a Podcast Special Airing June 1
2 minutes ago
J.P. Morgan Announces 2026 Summer Reading List and NextList Summer Series
2 minutes ago
Onfolio Signs Exclusive LOIs for Four Acquisitions Expected to Add Approximately $4.1 Million of Annual Adjusted EBITDA
2 minutes ago
B.o.s. Better Online Solutions BOS Expands RFID Division to Israel’s Defense Sector
2 minutes ago
Inside information: Suominen is planning to accelerate its Full Potential Program execution through a fully underwritten rights issue of up to EUR 28 million
3 minutes ago
22nd Century Group (Nasdaq: XXII) Expands High-Margin Pinnacle Platform With Launch of Pinnacle Pure at Major U.S. Retailers
3 minutes ago
Volato Group Confirms $5.5 Million Pro-Forma Cash Balance at March 31, 2026 for $0.14 Cash per Share Value
3 minutes ago
ASUS Brings Its Latest Chromebooks to Walmart
4 minutes ago
Tigo Energy Delivers American Designed and Assembled Optimizers to U.S. Customer
4 minutes ago
Neurocrine Biosciences, Inc. Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
28 minutes ago
Dogwood Therapeutics, Inc. Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
29 minutes ago
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
29 minutes ago
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
29 minutes ago
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
29 minutes ago
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
30 minutes ago
Ralliant Spotlights Award of $27.3M Investment from the Defense Production Act to Scale Production at its PacSci EMC Operating Company
32 minutes ago
The Biology Came First.
32 minutes ago
Translate
